Appointment of Joint Corporate Broker

August 21, 2024
PDF Version
RNS Number : 1687B
Renalytix PLC
21 August 2024
 

Renalytix plc

("Renalytix" or the "Company")

 

Appointment of Joint Corporate Broker

 

LONDON and NEW YORK, 21 August 2024 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces the appointment of Oberon Capital (a trading name of Oberon Investments Limited) as Joint Corporate Broker with immediate effect.

 

 

For further information, please contact:

 

Renalytix plc

www.renalytix.com

James McCullough, CEO

Via Walbrook PR



Stifel (Nominated Adviser and Joint Broker)

Tel: 020 7710 7600

Nicholas Moore / Nick Harland / Ben Good

 


 

Oberon Capital (Joint Broker)

Tel: 020 3179 5300

Mike Seabrook / Nick Lovering

 

 

Investec Bank plc (Joint Broker)

Tel: 020 7597 4000

Gary Clarence / Shalin Bhamra

 


 

Walbrook PR Limited

Tel: 020 7933 8780 or renalytix@walbrookpr.com

Alice Woodings / Charlotte Edgar

Mob: 07407 804 654 / 07884 664 686



CapComm Partners


Peter DeNardo

 

Tel: 415-389-6400 or investors@renalytix.com

 

About Renalytix

Renalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics and laboratory services company that is the global founder and leader in the new field of bioprognosis™ for kidney health. The leadership team, with a combined 200+ years of healthcare and in-vitro diagnostic experience, has designed its KidneyIntelX laboratory developed test to enable risk assessment for rapid progressive decline in kidney function in adult patients with T2D and early CKD (stages 1-3). We believe that by understanding how disease will progress, patients and providers can take action early to improve outcomes and reduce overall health system costs. For more information, visit www.renalytix.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
APPPMMLTMTMTBTI